N/A N=22 Randomized Double-blind Treatment

Treatment of Hypovitaminosis D in Rheumatoid Arthritis

Rheumatoid Arthritis · Hypovitaminosis D

Bottom Line

View on ClinicalTrials.gov: NCT00423358 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Aug 2015

Primary outcome: Primary: Parathyroid Hormone Level — 19; 20 pg/mL

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: Vitamin D (Dietary_supplement); placebo (Dietary_supplement)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: University of Wisconsin, Madison
Primary completion: Aug 2008

Outcome Measures

Outcome	Result	p-value
PRIMARY Parathyroid Hormone Level	19; 20	—
SECONDARY Bone Mineral Density	0.970; 1.151	—
SECONDARY Short Form 36 Survey	39.1; 47.7	—

Summary

This study recruits individuals with rheumatoid arthritis (RA) and low vitamin D concentrations. Subjects are dosed with vitamin D or placebo for one year. Primary outcome is change in bone turnover markers, additionally, bone mineral density and parameters of RA status are evaluated throughout the study.

Eligibility Criteria

Inclusion Criteria

Rheumatology

Exclusion Criteria

Bisphosphonate therapy

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00423358). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.